Wave down on Phase I safety data for DMD therapy

Following a setback last week for its Huntington disease program, Wave lost $9.55 (28%) to $24.47 on Tuesday after the company announced plans to test two lower doses of suvodirsen in a Phase II/III trial after final Phase I data revealed toxicity concerns with higher doses of the Duchenne muscular dystrophy candidate.